Consumer medicine information

Phenylephrine Baxter

Phenylephrine hydrochloride

BRAND INFORMATION

Brand name

Phenylephrine Baxter

Active ingredient

Phenylephrine hydrochloride

Schedule

SUMMARY CMI

PHENYLEPHRINE BAXTER

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. What PHENYLEPHRINE BAXTER is used for?

PHENYLEPHRINE BAXTER contains the active ingredient phenylephrine hydrochloride. PHENYLEPHRINE BAXTER is used to;

Help increase your blood pressure
Slow down your heart

For more information, see Section 1. What PHENYLEPHRINE BAXTER is used for? in the full CMI.

2. What should I know before I am given PHENYLEPHRINE BAXTER?

Do not use if you have ever had an allergic reaction to PHENYLEPHRINE BAXTER or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. Your doctor will discuss the risks and benefits of being given PHENYLEPHRINE BAXTER during pregnancy and in case of breastfeeding.

For more information, see Section 2. What should I know before I am given PHENYLEPHRINE BAXTER? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with PHENYLEPHRINE BAXTER and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How am I given PHENYLEPHRINE BAXTER?

PHENYLEPHRINE BAXTER can be given to you in three ways: a) as a slow injection or infusion (drip) into a vein, b) as a deep injection into a muscle; c) as an injection just under the skin. Sometimes it is diluted before use and given with fluids into a vein.
Your doctor will determine how you will be given this medicine. PHENYLEPHRINE BAXTER must only be given by a doctor or nurse.

More instructions can be found in Section 4. How am I given PHENYLEPHRINE BAXTER? in the full CMI.

5. What should I know whilst being given PHENYLEPHRINE BAXTER?

Things you should do	Remind any doctor, dentist or pharmacist, when you visit that you are using PHENYLEPHRINE BAXTER. Tell your doctor if you are pregnant or intend to become pregnant. Tell your doctor if you experience any problems with this medicine.
Things you should not do	You should not be given PHENYLEPHRINE BAXTER if you are allergic to phenylephrine, sodium metabisulfite or any of the ingredients listed at the end of this leaflet. You must not be given PHENYLEPHRINE BAXTER if you have very high blood pressure or a very fast heart beat (palpitations). If you are not sure whether you should start taking this medicine, talk to your doctor.
Driving or using machines	No specific studies have been conducted to assess the direct effect of phenylephrine hydrochloride on the ability to drive and use machines. However, adverse effects of phenylephrine hydrochloride include dizziness and drowsiness which could affect the ability to drive or use machines.
Looking after your medicine	PHENYLEPHRINE BAXTER should only be given to you in hospital. It will be stored in a cool dry place away from the light, where the temperature stays below 25°C. The vials should not be taken out of the box until just before they are to be used. This is because the medicine is affected by light.

For more information, see Section 5. What should I know whilst being given PHENYLEPHRINE BAXTER? in the full CMI.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

FULL CMI

PHENYLEPHRINE BAXTER

Active ingredient(s): phenylephrine hydrochloride

Consumer Medicine Information (CMI)

This leaflet provides important information about using PHENYLEPHRINE BAXTER. It does not contain all of the available information. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using PHENYLEPHRINE BAXTER.

Where to find information in this leaflet:

1. What PHENYLEPHRINE BAXTER is used for?
2. What should I know before I am given PHENYLEPHRINE BAXTER?
3. What if I am taking other medicines?
4. How am I given PHENYLEPHRINE BAXTER?
5. What should I know whilst being given PHENYLEPHRINE BAXTER?
6. Are there any side effects?
7. Product details

1. What PHENYLEPHRINE BAXTER is used for?

PHENYLEPHRINE BAXTER contains the active ingredient phenylephrine hydrochloride. PHENYLEPHRINE BAXTER is used to help increase your blood pressure and slow down your heart, for example, during surgery or in state of shock. It does this by causing constriction (narrowing) of your blood vessels.

It belongs to a group of medicines called vasoconstrictors.

Ask your doctor if you have any questions about why PHENYLEPHRINE BAXTER has been prescribed for you. Your doctor may have prescribed it for another reason.

This medicine is not addictive.

This medicine is available only with a doctor's prescription.

2. What should I know before I am given PHENYLEPHRINE BAXTER?

When you must not be given it

You must not be given PHENYLEPHRINE BAXTER if you are allergic to:

phenylephrine
sodium metabisulfite
any of the ingredients listed at the end of this leaflet

Symptoms of an allergic reaction may include:

shortness of breath, wheezing or difficulty breathing
swelling of the face, lips, tongue or other parts of the body
rash, itching or hives on the skin.

You must not be given PHENYLEPHRINE BAXTER if you have:

very high blood pressure
a very fast heartbeat (palpitations)

If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you are given it

Tell your doctor if you have, or have had, any medical conditions, especially the following:

thyroid disease
slow heart rate
other heart disease
severe arteriosclerosis (a disease of the arteries)

Fertility, pregnancy and breastfeeding

Tell your doctor if you are pregnant or intend to become pregnant. Your doctor will discuss the risks and benefits of being given PHENYLEPHRINE BAXTER during pregnancy.

Tell your doctor if you are breastfeeding or intend to breast-feed. Your doctor will discuss the risks and benefits of being given PHENYLEPHRINE BAXTER when breastfeeding.

If you have not told your doctor or nurse about any of the above, tell them before you are given PHENYLEPHRINE BAXTER.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and PHENYLEPHRINE BAXTER may interfere with each other. These include:

certain medicines to treat depression (such as monoamine oxidase inhibitors and tricyclic antidepressants).
halothane anaesthetics (a type of medicine used as an anaesthetic)
certain medicines used to stimulate labour in pregnant women.

These medicines may be affected by PHENYLEPHRINE BAXTER or affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor or pharmacist has more information on medicines to be careful with or avoid, while using PHENYLEPHRINE BAXTER.

4. How am I given PHENYLEPHRINE BAXTER?

How PHENYLEPHRINE BAXTER is given

PHENYLEPHRINE BAXTER can be given to you in three ways:

as a slow injection or infusion (drip) into a vein
as a deep injection into a muscle or
as an injection just under the skin.

Sometimes it is diluted before use and given with fluid into a vein. Your doctor will determine how you will be given this medicine. It may depend on why you need to use this drug.

PHENYLEPHRINE BAXTER must only be given by a doctor or nurse.

How much PHENYLEPHRINE BAXTER is given

Your doctor will decide what dose and how long you will receive PHENYLEPHRINE BAXTER. The dose will be different, depending on how your doctor gives you PHENYLEPHRINE BAXTER and why you are being given it.

If you take too much PHENYLEPHRINE BAXTER (overdose)

As this medicine is given to you under the supervision of your doctor, it is very unlikely that you will receive too much. However, if you experience any side effects after being given it, tell your doctor immediately.

If you think that you have been given too much PHENYLEPHRINE BAXTER, you may need urgent medical attention.

You should immediately:

phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

Symptoms of overdose include sensation of fullness in the head, tingling in the hands or feet and irregular or fast heart beat.

5. What should I know whilst being given PHENYLEPHRINE BAXTER?

Things you should do

Your doctor will monitor your blood pressure closely while you are being given PHENYLEPHRINE BAXTER.

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are being given PHENYLEPHRINE BAXTER.

Tell any other doctors, dentists and pharmacists who treat you that you are being given this medicine.

Driving or using machines

Be careful driving or operating machinery until you know how PHENYLEPHRINE BAXTER affects you. Make sure you know how you react to PHENYLEPHRINE BAXTER before you drive, operate machinery or do anything else that could be dangerous.

Looking after your medicine

PHENYLEPHRINE BAXTER should only be given to you in hospital. It will be stored in a cool dry place away from the light, where the temperature stays below 25°C.
The vials should not be taken out of the box until just before they are to be used. This is because the medicine is affected by light.
Follow the instructions in the carton on how to take care of your medicine properly.

When to discard your medicine

Do not use this medicine if the expiry date printed on the pack has passed.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Reconstituted and further diluted solutions that show discoloration, haziness, visible particulate matter or precipitation should not be used.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effects	What to do
Headache Restlessness Excitability	Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects	What to do
Fast or irregular heartbeats (also called palpitations) Very slow pulse Sensation of fullness in the head Tingling in the hands or feet	Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What PHENYLEPHRINE BAXTER contains

Active ingredient (main ingredient)	Phenylephrine Hydrochloride
Other ingredients (inactive ingredients)	sodium metabisulfite, sodium chloride, sodium citrate dihydrate, citric acid monohydrate, hydrochloric acid, sodium Hydroxide, water for injections.

Do not take this medicine if you are allergic to any of these ingredients.

What PHENYLEPHRINE BAXTER looks like

PHENYLEPHRINE BAXTER is a clear, colourless, aqueous solution, free from visible particulate, in sterile form for parenteral injection.

PHENYLEPHRINE BAXTER is presented in USP type I clear tubular glass vials with 13mm dark grey serum rubber stopper and 13 mm flip-off dark green seals. 25 vials of 1 mL fill single dose vials are packed into a printed carton.

A printed package insert is enclosed in the printed cartons.

PHENYLEPHRINE BAXTER Registration Number: 393130

Who distributes PHENYLEPHRINE BAXTER

Baxter Healthcare Pty Ltd
1 Baxter Drive
OLD TOONGABBIE NSW 2146
AUSTRALIA

This leaflet was prepared in July 2022.

Published by MIMS August 2024

BRAND INFORMATION

Brand name

Phenylephrine Baxter

Active ingredient

Phenylephrine hydrochloride

Schedule

1 Name of Medicine

Phenylephrine hydrochloride.

2 Qualitative and Quantitative Composition

1 vial of 1 mL contains 10 mg of phenylephrine hydrochloride.

Excipient with known effect.

Sodium metabisulfite.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution for injection.
Phenylephrine Baxter is a vasoconstrictor and pressor drug chemically related to adrenaline and ephedrine. Phenylephrine Baxter is a clear, colorless, aqueous solution, free from visible particulates, in sterile form for parenteral injection.
Phenylephrine Baxter contains no antimicrobial preservative.

4 Clinical Particulars

4.1 Therapeutic Indications

Phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anaesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, or hypersensitivity. It is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anaesthesia, and as a vasoconstrictor in regional analgesia.

4.2 Dose and Method of Administration

Dosage.

Mild or moderate hypotension.

Subcutaneously or intramuscularly.

Usual dose, from 2 mg to 5 mg. Range, from 1 mg to 10 mg. Initial dose should not exceed 5 mg.

Intravenously.

Usual dose, 0.2 mg. Range, from 0.1 mg to 0.5 mg. Initial dose should not exceed 0.5 mg.
Injections should not be repeated more often than every 10 to 15 minutes. A 5 mg intramuscular dose should raise blood pressure for one to two hours. A 0.5 mg intravenous dose should elevate the pressure for about 15 minutes.
Severe hypotension and shock - including medicine-related hypotension. Blood volume depletion should always be corrected as fully as possible before any vasopressor is administered. When, as an emergency measure, intra-aortic pressures must be maintained to prevent cerebral or coronary artery ischemia, phenylephrine hydrochloride can be administered before and concurrently with blood volume replacement.
Hypotension and occasionally severe shock may result from overdosage or idiosyncrasy following the administration of certain drugs, especially adrenergic and ganglion blocking agents, rauwolfia and veratrum alkaloids, and phenothiazine tranquilizers. Patients who receive a phenothiazine derivative as preoperative medication are especially susceptible to these reactions. As an adjunct in the management of such episodes, phenylephrine hydrochloride is a suitable agent for restoring blood pressure.
Higher initial and maintenance doses of phenylephrine hydrochloride are required in patients with persistent or untreated severe hypotension or shock. Hypotension produced by powerful peripheral adrenergic blocking agents, chlorpromazine, or phaeochromocytomectomy may also require more intensive therapy.

Continuous infusion.

Add 10 mg of the drug (1 mL of 1% solution) to 500 mL of glucose 5% injection, or sodium chloride 0.9% injection (providing a 1:50,000 solution equivalent to 20 micrograms per mL). To raise the blood pressure rapidly, start the infusion at about 100 micrograms to 180 micrograms per minute (based on 20 drops per mL this would be 100 to 180 drops per minute). When the blood pressure is stabilized (at a low normal level for the individual), a maintenance rate of 40 micrograms to 60 micrograms per minute usually suffices (based on 20 drops per mL this would be 40 to 60 drops per minute). If the drop size of the infusion system varies from the 20 drops per mL, the dose must be adjusted accordingly.
If a prompt initial pressor response is not obtained, additional increments of phenylephrine hydrochloride (10 mg or more) are added to the infusion bottle. The rate of flow is then adjusted until the desired blood pressure level is obtained. (In some cases, a more potent vasopressor, such as norepinephrine bitartrate, may be required.) Hypertension should be avoided. The blood pressure should be checked frequently. Headache and/or bradycardia may indicate hypertension. Arrhythmias are rare.
Spinal anaesthesia-hypotension. Routine parenteral use of phenylephrine hydrochloride has been recommended for the prophylaxis and treatment of hypotension during spinal anaesthesia. It is best administered subcutaneously or intramuscularly three or four minutes before injection of the spinal anaesthetic. The total requirement for high anaesthetic levels is usually 3 mg, and for lower levels, 2 mg. For hypotensive emergencies during spinal anaesthesia, phenylephrine hydrochloride may be injected intravenously, using an initial dose of 0.2 mg. Any subsequent dose should not exceed the previous dose by more than 0.1 mg to 0.2 mg and no more than 0.5 mg should be administered in a single dose. To combat hypotension during spinal anaesthesia in children, a dose of 0.5 mg to 1 mg per 25 pounds (approx 11 kg) body weight, administered subcutaneously or intramuscularly, is recommended.
Prolongation of spinal anaesthesia. The addition of 2 mg to 5 mg of phenylephrine hydrochloride to the anaesthetic solution increases the duration of motor block by as much as approximately 50 percent without any increase in the incidence of complications such as nausea, vomiting, or blood pressure disturbances.
Vasoconstrictor for regional analgesia. Concentrations about ten times those employed when adrenaline is used as a vasoconstrictor are recommended. The optimum strength is 1:20,000 (equivalent to 50 micrograms per mL) made by adding 1 mg of phenylephrine hydrochloride to every 20 mL of local anaesthetic solution. Some pressor responses can be expected when 2 mg or more are injected.
Paroxysmal supraventricular tachycardia. Rapid intravenous injection (within 20 to 30 seconds) is recommended; the initial dose should not exceed 0.5 mg, and subsequent doses, which are determined by the initial blood pressure response, should not exceed the preceding dose by more than 0.1 mg to 0.2 mg, and should never exceed 1 mg.

Paediatric use.

To combat hypotension during spinal anaesthesia in children, a dose of 0.5 mg to 1 mg per 25 pounds (approx 11 kg) body weight, administered subcutaneously or intramuscularly, is recommended.

Method of administration.

It is for use in one patient on one occasion only. Discard any residue.
Phenylephrine hydrochloride is generally injected subcutaneously, intramuscularly, slowly intravenously, or in dilute solution as a continuous intravenous infusion. In patients with paroxysmal supraventricular tachycardia and, if indicated, in case of emergency, phenylephrine hydrochloride is administered directly intravenously. The dose should be adjusted according to the pressor response. See Table 1.

For convenience in intermittent intravenous administration, dilute 1 mL Phenylephrine Baxter (1%) with 9 mL sterile water for injection, to yield 0.1% phenylephrine hydrochloride. See Table 2.

4.3 Contraindications

Phenylephrine hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it.

4.4 Special Warnings and Precautions for Use

If used in conjunction with oxytocic medicines, the pressor effect of sympathomimetic pressor amines is potentiated (see Section 4.6 Fertility, Pregnancy and Lactation). The obstetrician should be warned that some oxytocic drugs may cause severe persistent hypertension and that even a rupture of a cerebral blood vessel may occur during the postpartum period.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

General.

Phenylephrine hydrochloride should be employed only with extreme caution in elderly patients or in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis.

Use in hepatic impairment.

No data available.

Use in renal impairment.

No data available.

Use in the elderly.

No data available.

Paediatric use.

No data available.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anaesthesia and therefore should be used only with great caution or not at all.

Oxytocic medicines.

The pressor effect of sympathomimetic pressor amines is potentiated (see Section 4.4 Special Warnings and Precautions for Use).

MAO inhibitors.

The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). Therefore, when initiating pressor therapy in these patients, the initial dose should be small and used with due caution. The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category B2)
Animal reproduction studies have not been conducted with phenylephrine hydrochloride. It is also not known whether phenylephrine hydrochloride can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.
Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.
It is not known whether this medicine is excreted in human milk. Because many are excreted in human milk, caution should be exercised when phenylephrine hydrochloride is administered to a nursing woman.
If vasopressor drugs are either used to correct hypotension or added to the local anaesthetic solution, the obstetrician should be cautioned that some oxytocic drugs may cause severe persistent hypertension and that even a rupture of a cerebral blood vessel may occur during the postpartum period (see Section 4.4 Special Warnings and Precautions for Use).

4.7 Effects on Ability to Drive and Use Machines

No data available.

4.8 Adverse Effects (Undesirable Effects)

Headache, reflex bradycardia, excitability, restlessness, and rarely arrhythmias.

Reported suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.

4.9 Overdose

The oral LD₅₀ in the rat is 350 mg/kg, in the mouse 120 mg/kg.
Overdosage may induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities. Should an excessive elevation of blood pressure occur, it may be immediately relieved by an α-adrenergic blocking agent, e.g. phentolamine.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Phenylephrine hydrochloride produces vasoconstriction that lasts longer than that of adrenaline and ephedrine. Responses are more sustained than those to adrenaline, lasting 20 minutes after intravenous and as long as 50 minutes after subcutaneous injection. Its action on the heart contrasts sharply with that of adrenaline and ephedrine, in that it slows the heart rate and increases the stroke output producing no disturbance in the rhythm of the pulse.
Phenylephrine hydrochloride is a powerful postsynaptic alpha-receptor stimulant with little effect on the beta-receptors of the heart. In therapeutic doses, it produces little if any stimulation of either the spinal cord or cerebrum. A singular advantage of this drug is the fact that repeated injections produce comparable effects.
The predominant actions of phenylephrine hydrochloride are on the cardiovascular system. Parenteral administration causes a rise in systolic and diastolic pressures in man and other species. Accompanying the pressor response to phenylephrine hydrochloride is a marked reflex bradycardia that can be blocked by atropine; after atropine, large doses of phenylephrine hydrochloride increase the heart rate only slightly. In man, cardiac output is slightly decreased and peripheral resistance is considerably increased. Circulation time is slightly prolonged, and venous pressure is slightly increased; venous constriction is not marked. Most vascular beds are constricted; renal splanchnic, cutaneous, and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised.
The drug is a powerful vasoconstrictor, with properties very similar to those of norepinephrine but almost completely lacking the chronotropic and inotropic actions on the heart. Cardiac irregularities are seen only very rarely even with large doses.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

No data available.

Distribution.

No data available.

Metabolism.

No data available.

Excretion.

No data available.

5.3 Preclinical Safety Data

No long-term animal studies have been done to evaluate the potential of phenylephrine hydrochloride in these areas.

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sodium chloride, sodium metabisulfite, sodium citrate dihydrate, citric acid monohydrate, hydrochloric acid, sodium hydroxide, water for injections.

6.2 Incompatibilities

No data available.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.
Protect from light if removed from the packaging.

6.5 Nature and Contents of Container

Phenylephrine Baxter contains 10 mg/1 mL phenylephrine hydrochloride and is available in Type I clear glass vials with a rubber stopper in cartons of 25 vials.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.

Chemical name: (-)-m-hydroxy-α-[(methylamino)methyl] benzyl alcohol hydrochloride.
Molecular formula: C₉H₁₃NO₂.HCl.
Molecular weight: 203.7.

Service Unavailable

Consumer medicine information

Phenylephrine Baxter

Phenylephrine hydrochloride

Keep track of your medicines

BRAND INFORMATION